ASH: Beam’s Base Editor Efficacy In Sickle Cell Disease Holds Up

Next-Gen Program Aims To ESCAPE Busulfan Conditioning

 
• By Mandy Jackson
  
Base editing may give Beam a competitive edge in sickle cell disease (Shutterstock)

More from Clinical Trials

More from Conferences